<DOC>
	<DOC>NCT02245568</DOC>
	<brief_summary>The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.</brief_summary>
	<brief_title>Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia, Primary Progressive</mesh_term>
	<mesh_term>Pick Disease of the Brain</mesh_term>
	<criteria>Subjects with all cause dementia and probable Alzheimer's disease at enrollment and who completed participation in one of the following three TauRx studies (inclusive of the 4week posttreatment followup visit): TRx237005, TRx237008, or TRx237015. Subjects with a diagnosis of probable bvFTD at enrollment and who completed participation in TauRx study TRx237007 through Visit 9 (Week 52). Females, if of childbearing potential, must practice true abstinence or continue to use adequate contraception and agree to maintain this throughout the study Subject, and/or, in the case of reduced decisionmaking capacity, legally acceptable representative(s) consistent with national law and ethics approval is/are able to read, understand, and provide written informed consent Has an identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥1 hour/day ≥3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug Able to comply with the study procedures History of swallowing difficulties Pregnant or breastfeeding Clinically significant laboratory, pulse cooximetry, electrocardiogram, or imaging abnormality (in originating study) or emergent intercurrent illness that, in the judgment of the principal investigator, could result in the risk of participation outweighing the potential benefit Current participation in, or intent to enroll in, another clinical trial of a drug, biologic, device, or medical food In Germany, subjects mandated to reside in a continuous care or assisted living facility or those whose willingness to participate in the clinical trial may be unduly influenced</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer Disease</keyword>
	<keyword>bvFTD</keyword>
	<keyword>Frontotemporal Dementia</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Cognitive Disorders</keyword>
</DOC>